Content
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. Danaher shares have lost about 4.2% since the beginning of the year versus the S&P 500’s gain of 7.8%. After this year, when COVID headwinds fade, I expect the stock to restart a meaningful uptrend, hopefully, supported by higher general economic growth expectations.
- Information is provided ‚as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed.
- While margins were down, the company saw healthy demand and none of the funding issues that pressured its Biotechnology segment.
- The Style Scores are a complementary set of indicators to use alongside the Zacks Rank.
- The company generated $1.7 billion of free cash flow in the first quarter, which translates to a decline of 3.0%.
- Also, its performance was lackluster, as investors aren’t keen on holding growth stocks in a high-rate environment.
- There are currently 3 hold ratings and 13 buy ratings for the stock.
These are subject to change due to a number of reasons but are provided as the best of date according to current knowledge. The Analyst score is an aggregation of the available sell-side analyst ratings (provided by Benzinga). The arrow represents the current price quote (delayed by 20 minutes).
Analyst’s Opinion
The company operates through three segments, including Life Sciences, Diagnostics, and Environmental & Applied Solutions. However, I am taking advantage of the stock price decline and am excited to increase my investment in Danaher. The company’s core business remains strong thanks to the secular growth in various sectors, and even its industrial segment has done well, as it has avoided general economic weakness. 16 Wall Street equities research analysts have issued „buy,” „hold,” and „sell” ratings for Danaher in the last year.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians’ offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. The company was founded in 1969 and is headquartered in Washington, the District of Columbia.
Danaher downgraded to neutral from buy at BofA Securities
This means that over the past quarter there has been an increase of insiders selling their shares of DHR in relation to earlier this year. Last month, Daniel Raskas, the SVP – Corporate Development of DHR sold 19,847.00 shares for a total of $4,535,039.50. The life sciences and diagnostics company’s guidance is getting complicated. Its revenue broke down by 10% basis points of this came from core weakness. What’s interesting is that this segment was significantly impacted by COVID.
While the valuation is fair, we’re not at prices that I would call attractive. I think DHR can go there if the market continues to weaken. That said, the company’s valuation has erased the entire surge caused by the pandemic. The implied price/free cash flow ratio is back to 2019 levels. As a result, Cepheid’s respiratory testing revenue of approximately $550 million in the quarter exceeded our expectation of $450 million. This was driven both by higher volumes and the preference for our 4-in-1 test for COVID-19, Flu A and B and RSV.
Research Reports for DHR
In other words, the biotechnology segment is seeing some unwinding COVID-related benefits that are amplified by a very challenging funding (high rates) environment. We’d like to share more about how we work and what drives our day-to-day business. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. The good news is that free cash flow is expected to continue growing. This year, the company is estimated to generate $7.8 billion in free cash flow, followed by consistent high-single-digit growth in the next few years.
- Currently, Danaher has a market capitalization of $176.23 billion.
- It shows how much a company is earning per all outstanding share.
- Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide.
- The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.
- All ratings classes are provided by Benzinga and aggregated by TradeStation.
This represents a $1.08 annualized dividend and a yield of 0.45%. The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. There’s life after COVID-19 for Danaher, and the stock has a long pathway of growth ahead of it. On a risk/reward basis, they aren’t a great value right now, but these are excellent stocks to watch for a better entry point on. This is provided by Benzinga, and is indicative of the reason that the relevant security is potentially moving in any direction.
Currently, the analyst consensus on Danaher is a Strong Buy with an average price target of $277.76, representing a 18.46% upside. In a report released on July 6, Evercore ISI also maintained a Buy rating on the stock with a $260.00 price target. The good news is that I’m finally getting another opportunity to add DHR shares. DHR has become my second-smallest position, as I haven’t added a lot to the position in recent months. Also, its performance was lackluster, as investors aren’t keen on holding growth stocks in a high-rate environment. The featured stocks all trade at substantial discounts to analyst price targets.
Stock Money Flow
There are currently 3 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should „moderate buy” DHR shares. Strength was broad-based across both equipment and consumables, particularly in our industrial end markets. In its Life Science segment, the company reported 2.5% growth, boosted by 5.0% core revenue growth.
DHR earnings call for the period ending December 31, 2020. DHR earnings call for the period ending March 31, 2021. DHR earnings call for the period ending June 30, 2021.
Feel free to reach out to me via DMs or find me on Twitter (@Growth_Value_) for more insights. I anticipate that after 2023, Danaher’s stock price will rise again and outperform the market. In the meantime, I am eager to accumulate shares during any period of weakness. Furthermore, Radiometer experienced a significant increase in core growth driven by robust demand for blood gas testing in China. Similarly, Biosystems also observed mid-single-digit core growth, mainly led by advanced staining and digital pathology.
This helps the valuation, as it would imply that the company trades at just 22x 2023E free cash flow. Last but not least, one of my favorite segments, Environmental & Applied Solutions, performed very well. This segment saw 5.0% revenue growth, as forex headwinds of 200 basis points offset 6.5% higher core growth. Margins improved by 420 basis points, most of which came from higher core margins. One major issue was related to the challenging macroeconomic environment, as the company witnessed softer demand globally at many of its emerging biotech customers. Pressures on liquidity and funding accelerated their efforts to conserve capital leading to project delays and cancellations.
Stock Funds That Flip-Flopped in the Rankings
See which 3 stocks are most likely to make moves following their insider activities. McNamara covers the Healthcare sector, focusing on stocks such as Thermo Fisher, Bio-Rad Laboratories, and Danaher. According to TipRanks, McNamara has an average return https://g-markets.net/helpful-articles/how-to-use-trading-chart-continuation-patterns/ of -8.6% and a 15.63% success rate on recommended stocks. One share of DHR stock can currently be purchased for approximately $238.88. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.
The total number of shares available for this security. The Price to Earnings ratio is generally considered an indicator of the value of a security (whether it is over or undervalued). This is calculated by dividing the current price quote by the Earnings per Share.